FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2949348362> ?p ?o ?g. }

• W2949348362 abstract "Background: Brinzolamide as a carbonic anhydrase inhibitor could be combined with other intraocular pressure (IOP) lowering drugs for glaucoma and ocular hypertension (OHT), but the efficacy was controversial. So, this study was used to assess the efficacy and safety of brinzolamide as add-on to prostaglandin analogues (PGAs) or β-blocker in treating patients with glaucoma or OHT who fail to adequately control IOP. Methods: We searched PubMed, Embase, MEDLINE, Cochrane Library, and clinicaltrials.gov from inception to October 4, 2018. Randomized controlled trials of brinzolamide as add-on to PGAs or β-blocker for glaucoma and OHT were included. Meta-analysis was conducted by RevMan 5.3 software. Results: A total of 26 trials including 5,583 patients were analyzed. Brinzolamide produced absolute reductions of IOP as an adjunctive therapy for patients with glaucoma or OHT. Brinzolamide and timolol were not significantly different in lowering IOP as add-on to PGAs (9 am: P = 0.07; 12 am: P = 0.66; 4 pm: P = 0.66). Likewise, brinzolamide was as effective as dorzolamide in depressing IOP (9 am: P = 0.59; 12 am: P = 0.94; 4 pm: P = 0.95). For the mean diurnal IOP at the end of treatment duration, there were no statistical differences in above comparisons (P > 0.05). Compared with brimonidine (b.i.d.), there was a significant reduction of IOP in brinzolamide (b.i.d.) at 9 am (P < 0.0001); however, the difference was cloudy in thrice daily subgroup (P = 0.44); at 12 am, brinzolamide (b.i.d.) was similar to brimonidine (b.i.d.) in IOP-lowering effect (P = 0.23), whereas brimonidine (t.i.d.) led to a greater effect than brinzolamide (t.i.d.) (P = 0.02). At 4 pm, brinzolamide (b.i.d.) was superior IOP-lowering effect compared with brimonidine (b.i.d.) (P = 0.0003); conversely, the effect in brinzolamide (t.i.d.) was lower than brimonidine (t.i.d.) (P < 0.0001). For the mean diurnal IOP, brinzolamide was lower in twice daily subgroup (P < 0.00001); brimonidine was lower in thrice daily subgroup (P < 0.00001). With regard to the safety, brinzolamide and dorzolamide had a higher incidence of taste abnormality; moreover, brinzolamide resulted in more frequent blurred vision; dorzolamide resulted in more frequent ocular discomfort and eye pain. Timolol resulted in more frequent blurred vision and less conjunctival hyperemia. Brimonidine resulted in more frequent ocular hyperemia. As to other adverse events (AEs) (conjunctivitis, eye pruritus, foreign body sensation in eyes, and treatment-related AEs), brinzolamide was similar to other three active comparators. Conclusions: Brinzolamide, as add-on to PGAs or β-blocker, significantly decreased IOP of patients with refractory glaucoma or OHT and the AEs were tolerable." @default.
• W2949348362 created "2019-06-27" @default.
• W2949348362 creator A5024229744 @default.
• W2949348362 creator A5032435039 @default.
• W2949348362 creator A5046857211 @default.
• W2949348362 creator A5048703887 @default.
• W2949348362 creator A5087568262 @default.
• W2949348362 date "2019-06-25" @default.
• W2949348362 modified "2023-10-16" @default.
• W2949348362 title "Efficacy and Safety of Brinzolamide as Add-On to Prostaglandin Analogues or β-Blocker for Glaucoma and Ocular Hypertension: A Systematic Review and Meta-Analysis" @default.
• W2949348362 cites W118958574 @default.
• W2949348362 cites W143215683 @default.
• W2949348362 cites W1498580312 @default.
• W2949348362 cites W186252241 @default.
• W2949348362 cites W1975908022 @default.
• W2949348362 cites W1976042967 @default.
• W2949348362 cites W1976649858 @default.
• W2949348362 cites W1978157711 @default.
• W2949348362 cites W1978608810 @default.
• W2949348362 cites W2012969262 @default.
• W2949348362 cites W2014449931 @default.
• W2949348362 cites W2019742314 @default.
• W2949348362 cites W2021015136 @default.
• W2949348362 cites W2022883354 @default.
• W2949348362 cites W2023323765 @default.
• W2949348362 cites W2025870925 @default.
• W2949348362 cites W2028124768 @default.
• W2949348362 cites W2030981277 @default.
• W2949348362 cites W2032965235 @default.
• W2949348362 cites W2034742711 @default.
• W2949348362 cites W2039015545 @default.
• W2949348362 cites W2046665700 @default.
• W2949348362 cites W2056827262 @default.
• W2949348362 cites W2058644237 @default.
• W2949348362 cites W2067542801 @default.
• W2949348362 cites W2075923684 @default.
• W2949348362 cites W2077659132 @default.
• W2949348362 cites W2079030429 @default.
• W2949348362 cites W2082744863 @default.
• W2949348362 cites W2083891344 @default.
• W2949348362 cites W2088463918 @default.
• W2949348362 cites W2090233897 @default.
• W2949348362 cites W2093740732 @default.
• W2949348362 cites W2098923148 @default.
• W2949348362 cites W2107869569 @default.
• W2949348362 cites W2118638775 @default.
• W2949348362 cites W2125435699 @default.
• W2949348362 cites W2135699266 @default.
• W2949348362 cites W2137199443 @default.
• W2949348362 cites W2151027803 @default.
• W2949348362 cites W2160605010 @default.
• W2949348362 cites W2164783993 @default.
• W2949348362 cites W2282194174 @default.
• W2949348362 cites W2323824345 @default.
• W2949348362 cites W2328969677 @default.
• W2949348362 cites W2419625350 @default.
• W2949348362 cites W2510449519 @default.
• W2949348362 cites W2588681363 @default.
• W2949348362 cites W2605201600 @default.
• W2949348362 cites W2731862025 @default.
• W2949348362 cites W2794022808 @default.
• W2949348362 cites W2884793927 @default.
• W2949348362 cites W2886612546 @default.
• W2949348362 cites W4233747915 @default.
• W2949348362 cites W84625781 @default.
• W2949348362 doi "https://doi.org/10.3389/fphar.2019.00679" @default.
• W2949348362 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6603202" @default.
• W2949348362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31293419" @default.
• W2949348362 hasPublicationYear "2019" @default.
• W2949348362 type Work @default.
• W2949348362 sameAs 2949348362 @default.
• W2949348362 citedByCount "10" @default.
• W2949348362 countsByYear W29493483622020 @default.
• W2949348362 countsByYear W29493483622021 @default.
• W2949348362 countsByYear W29493483622022 @default.
• W2949348362 countsByYear W29493483622023 @default.
• W2949348362 crossrefType "journal-article" @default.
• W2949348362 hasAuthorship W2949348362A5024229744 @default.
• W2949348362 hasAuthorship W2949348362A5032435039 @default.
• W2949348362 hasAuthorship W2949348362A5046857211 @default.
• W2949348362 hasAuthorship W2949348362A5048703887 @default.
• W2949348362 hasAuthorship W2949348362A5087568262 @default.
• W2949348362 hasBestOaLocation W29493483621 @default.
• W2949348362 hasConcept C118487528 @default.
• W2949348362 hasConcept C126322002 @default.
• W2949348362 hasConcept C168563851 @default.
• W2949348362 hasConcept C2776478404 @default.
• W2949348362 hasConcept C2776521421 @default.
• W2949348362 hasConcept C2776727336 @default.
• W2949348362 hasConcept C2778073030 @default.
• W2949348362 hasConcept C2778190193 @default.
• W2949348362 hasConcept C2778527774 @default.
• W2949348362 hasConcept C2781092963 @default.
• W2949348362 hasConcept C71924100 @default.
• W2949348362 hasConceptScore W2949348362C118487528 @default.
• W2949348362 hasConceptScore W2949348362C126322002 @default.
• W2949348362 hasConceptScore W2949348362C168563851 @default.
• W2949348362 hasConceptScore W2949348362C2776478404 @default.
• W2949348362 hasConceptScore W2949348362C2776521421 @default.
• W2949348362 hasConceptScore W2949348362C2776727336 @default.

• next